Philip Low: Sleep Analyzer

Founder, Chairman, and CEO, NeuroVigil, Age: 33

Written byKerry Grens
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

FRANK ROGOZIENSKI/WONDERFUL MACHINEPhilip Low was born in Vienna, grew up in Paris, and went to college in Chicago. Mirroring his early-life peregrinations, Low’s research has led him from math to neuroscience to business. In the late 1990s, while completing his undergraduate mathematics degree at the University of Chicago, Low spent a summer doing cancer research at Harvard Medical School. “Having worked in math and physics for most of my undergraduate years, studying something that was alive was very refreshing,” he says.

While the experience motivated him to pursue a career in biology, he got a sense that applying his computational skills to neuroscience would be more fruitful. “What I found from neuroscientists was they were excited to have mathematicians among them,” he says. METHODS: For graduate school, Low went to the Salk Institute for Biological Studies to study sleep patterns in zebra finches in the lab of Terry Sejnowski.1 While there he also seized upon a neuroscience problem for which math would come in handy: sleep analysis often required labor-intensive interpretations of data, and Low set out to develop an algorithm that could map sleep stages automatically. “I locked myself on the fifth floor of the Salk Institute and emerged with the solution 3 years later,” ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies